Latest Competition News

Chimeric Therapeutics reports promising interim results from its CHM CDH17 Phase 1/2 trial, with 75% disease control at 28 days and durable responses in gastrointestinal cancers.

Volt Group Limited has locked in a conditional $4 million placement to support its acquisition of 4D Delta, backed by strong institutional and director participation. The raise, priced at a discount to recent trading, aims to accelerate growth initiatives and strengthen working capital.

The ACCC has given informal clearance for the merger between Southern Cross Media Group and Seven West Media, marking a key regulatory milestone. The deal still awaits shareholder and ACMA approvals before completion.

The Australian Competition and Consumer Commission has given the green light to Southern Cross Media’s proposed acquisition of Seven West Media, marking a significant regulatory milestone in the evolving Australian media landscape.

Comms Group Limited reports a strong start to FY26 with a 41.6% revenue increase and successful integration of TasmaNet, positioning the company for ambitious annual targets.

NEXTDC reported robust FY25 results with 14% revenue growth and unveiled an ambitious 3GW expansion pipeline across Australia and Asia, positioning itself at the forefront of the AI infrastructure revolution.

NEXTDC’s 2025 AGM highlights a landmark year with 42% growth in contracted utilisation and a $6.4 billion funding base, alongside strategic board changes and a new incentive plan to secure leadership.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, finding limited competition concerns amid evolving digital media landscapes.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, citing limited competition concerns amid evolving digital media landscapes.

ReNerve Limited’s innovative NervAlign® Nerve Cuff has secured approval for use across the US Department of Defense and Veterans Affairs healthcare systems, marking a major milestone for the Australian medtech company.

Artrya Limited has expanded its SAPPHIRE clinical study with Ascension, one of the largest US non-profit health systems, joining as the fourth major participant. This move strengthens the study’s reach and advances the evaluation of Artrya’s AI-powered Salix platform for coronary artery disease detection.

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.